Written and medically reviewed by Dr. Diane Mueller, ND, LAc, DAOM, founder of MyLymeDoc. Last reviewed September 16, 2026.
Glutathione is a real, well-studied molecule with a genuine biochemical role in detoxification, and no clinical trial has tested it specifically in Lyme disease patients. Those two facts sit side by side and both matter. The rationale for using glutathione during Lyme treatment is built on solid general biochemistry, chronic infection can deplete the body’s antioxidant reserves, and glutathione is the body’s primary defense against that kind of oxidative stress. What has not been demonstrated is that supplementing it changes outcomes for someone being treated for Lyme disease specifically. This page walks through what is established, what is reasonable extrapolation, and what gets stated with more confidence online than the research actually supports.
Glutathione is a small molecule your body produces itself, made from three amino acids, and it functions as the primary antioxidant in nearly every cell. Understanding what it actually does helps separate the real biochemistry from the marketing language that often surrounds it.
The scientific literature describes glutathione’s function plainly: it “has the function of ‘master antioxidant’ in all tissues and is involved in antioxidant defense, detoxication of xenobiotics, intracellular redox homeostasis.” In practical terms, glutathione neutralizes damaging molecules called free radicals, and it also attaches itself to toxins in the liver so they can be cleared from the body, a step called phase two conjugation. This is legitimate, textbook liver physiology, not a wellness-industry invention. It sits inside the broader detoxification conversation that comes up throughout Lyme treatment, where glutathione is one piece among several, not the whole story.
Real hepatic detoxification happens in two documented phases, and glutathione’s role sits specifically in the second one. This is worth separating clearly from the vague “detox” language used in supplement marketing.
Phase one involves “functionalization, addition of oxygen to form a reactive site on the toxic compound,” which often makes a substance more reactive before it becomes safer. Phase two is conjugation, “adding a water-soluble group” so the substance can be excreted, and glutathione is one of the molecules the liver uses to do this. That two-step process is real biochemistry that happens in every functioning liver, constantly, whether or not you take a supplement.
Chronic infection can deplete glutathione, and the strongest evidence for this comes from research on a different infection entirely. This is where the Lyme-specific claim starts to stretch beyond what has actually been studied.
A study of chronic HIV infection found that “chronic HIV infection leads to excessive production of proinflammatory cytokines…leading to the depletion of GSH,” comparing thirteen HIV-positive patients against thirteen healthy controls. The same inflammatory burden shows up throughout chronic Lyme disease, which is the actual basis for extending this mechanism to Lyme patients. That is a real, human finding, and it demonstrates a mechanism, chronic inflammatory cytokine release depleting antioxidant reserves, that plausibly applies to other chronic infections. It was not studied in Lyme disease. Using it to support a Lyme-glutathione connection is a reasonable extrapolation from a related mechanism, not direct evidence.
Does supplementing actually raise glutathione levels in the body, and if so, how much? The clearest human data comes from healthy adults, not people being treated for an infection, and it shows a real but modest effect that depends heavily on the form used. A six-month randomized controlled trial in fifty-four healthy, non-smoking adults found that daily oral glutathione supplementation raised “blood, erythrocyte, and plasma glutathione levels by 30 to 35 percent” in the higher-dose group by the six-month mark. That took six months to show up.
A separate pilot study using a liposomal formulation, which wraps the molecule in a fat-based capsule to improve absorption, found levels rising faster: “GSH levels were elevated after 1 week with maximum increases of 40% in whole blood, 25% in erythrocytes, 28% in plasma and 100% in PBMCs.” That study had no placebo control and was conducted in healthy subjects, so treat it as a promising early signal on bioavailability, not proof of clinical benefit. Plain oral glutathione is broken down substantially in the digestive tract before it reaches the bloodstream, which is the biochemical reason liposomal, sublingual, and IV forms are used when raising blood levels quickly matters.
IV glutathione has a real safety track record in at least one well-controlled trial, and that same trial found no benefit on the condition it was tested for. Both facts are worth knowing before deciding whether IV therapy makes sense for you.
A randomized, double-blind trial of IV glutathione in Parkinson’s disease gave twenty-one participants 1,400 milligrams three times weekly for four weeks. The treatment “was well tolerated, with no withdrawals for adverse events,” but researchers found no significant difference in the primary motor-symptom outcome compared to placebo. This trial tells you IV glutathione has an acceptable safety profile in a supervised medical setting. It does not tell you it works for the condition it was tested on, and it was not tested in Lyme disease at all.
N-acetylcysteine, a common companion supplement used to support glutathione production, carries a documented and serious risk in people with asthma. This is the section most competing content leaves out entirely, and it matters.
A case report describes fatal bronchospasm following NAC use in an asthmatic patient, part of a broader pattern the literature confirms: “several cases of fatal bronchospasm have been reported in asthmatic patients after inhaled or intravenous N-acetylcysteine.” That is a single case report, the lowest tier of clinical evidence, but it represents a real and serious risk pattern that anyone with asthma should discuss with a clinician before starting NAC or a glutathione-precursor regimen.
This is a different pathway than mold-specific binders, which target mycotoxins directly rather than supporting the body’s own antioxidant system. Someone dealing with both Lyme and mold exposure may reasonably need both, sequenced correctly rather than combined all at once.
Glutathione is widely recommended for managing Herxheimer, or die-off, reactions during antimicrobial treatment, and the standard clinical reference on managing that reaction does not include it. This is the single clearest example of where clinical-practice tradition has outpaced the published research.
A Herxheimer reaction is a temporary worsening of symptoms, often fever, chills, and body aches, that can happen when antimicrobial treatment kills off a large number of bacteria at once and the immune system reacts to the debris.
Spirochetal lysis following antibiotic exposure leads to the release of “lipoproteins, endotoxin-like substances, and proinflammatory cytokines,” according to the current StatPearls clinical reference. That same reference lists the actual management approaches used in practice: supportive care, antipyretics, IV fluids, vasopressors in severe cases, and corticosteroids or anti-TNF antibodies for the most serious reactions. Glutathione does not appear anywhere in that list. Its use for Herxheimer management is a common integrative-medicine practice built on a plausible rationale, antioxidant support during a period of high inflammatory burden, not on trial evidence specific to this reaction.
What happens when you search the medical literature directly for glutathione trials in Lyme disease patients? Nothing comes up. This is the honest bottom line the rest of this page has been building toward, and it deserves to be stated without hedging.
No clinical trial testing glutathione supplementation in Lyme disease or borreliosis patients currently exists in the published literature. The closest available material is a case series mentioning glutathione IV as adjunctive support, with no control group and no measured outcomes to compare it against. Everything connecting glutathione to Lyme disease specifically, as opposed to chronic infection and inflammation generally, is extrapolation from adjacent research, reasonable extrapolation, but extrapolation.
Glutathione support has a plausible biochemical rationale for someone managing chronic infection and inflammation, and it belongs as one piece of a sequenced plan rather than a standalone intervention. In our practice, detoxification support fits into the broader phase of treatment that follows building the body’s baseline capacity, not before it and not in isolation from everything else happening in your care.
That sequencing is the same logic behind Dr. Mueller’s approach to Lyme treatment generally: build the body’s baseline capacity first, then layer in targeted support once that foundation is in place.
In practice, we see patients arrive having already tried a glutathione supplement on their own, sometimes helping, sometimes doing nothing they could notice, without ever having addressed the underlying exposure or infection burden it was meant to support. Sequencing matters more than the supplement itself.
If you are considering glutathione, liposomal glutathione, or IV therapy as part of your Lyme treatment, the honest starting point is a conversation about your specific history, current medications, and whether you have asthma or other conditions that change the risk picture. This page does not publish a dosing protocol, because that decision belongs with a clinician who knows your case. Book a consultation if you want to talk through whether it fits your plan.
No clinical trial has tested glutathione specifically in Lyme disease patients. The rationale is based on glutathione’s general antioxidant role and evidence that chronic infection depletes it in other conditions, not on direct Lyme-specific research.
Plain oral glutathione is broken down substantially before absorption. Liposomal and IV forms raise blood levels faster in the research that exists, though that research was conducted in healthy people, not Lyme patients specifically.
This is a common integrative-medicine practice, but the standard clinical reference for managing Herxheimer reactions does not list glutathione among its recommended treatments. Its use here is clinical tradition built on a plausible rationale, not trial evidence.
Glutathione itself is generally well tolerated in the research available. N-acetylcysteine, a common companion supplement, carries a documented bronchospasm risk in people with asthma, which is worth discussing with your clinician.
Not necessarily, but plain oral glutathione is poorly absorbed and a six-month trial in healthy adults showed only a gradual rise in blood levels. If raising levels more quickly matters for your situation, liposomal or IV forms have shown faster increases in early research.
Evidence from HIV research shows chronic infection can deplete glutathione through inflammatory cytokine release. This has not been specifically studied in Lyme disease, but the underlying mechanism plausibly applies to other chronic infections as well.
We have helped thousands of people in Colorado, Oregon, Wyoming, New Jersey, Pennsylvania, Texas, and Wisconsin restore their health and quality of life by diagnosing and treating their Lyme Disease.
We have helped thousands of
people restore their health
and quality of life by diagnosing
and treating their Lyme Disease.
“Dr. Mueller’s approach to medicine is refreshing! There is only so much you can do with western medicine and in my life I was needing a new approach. By addressing the whole body, nutritional diet factors, environmental factors, blood work, and incorporating ideas I had not previously known, I was able to break through with my conditions. I am not only experiencing less pain in my life, but through the process of healing guided by Dr. Diane Mueller, I am now happy to say I have more consciousness surrounding how I eat, what to eat and when things are appropriate. Living by example Dr. Mueller has a vibrancy that makes you want to learn and know more about your body and overall health. I highly recommend her to anyone looking for new answers, a new approach to health, or in need of freedom from pain and limitations.”
-Storie S.
Kihei, HI
